The Dana-Farber Cancer Institute (DFCI) was designated as a comprehensive cancer center by the National Cancer Institute in 1973. Two years later, in 1975, the Institute was initially awarded an Institutional National Research Service Award (T32 CAO9172) by the National Cancer Institute. Since that time, 229 individuals have been supported by this grant and this funding mechanism has become an essential component in the ability of the Institute to develop clinical investigators. The purpose of this proposal is to request continued support for another five years to provide research training in a comprehensive cancer center for postgraduate physicians who desire a career in academic oncology. The specific purpose of this application is to offer an experience in clinical or laboratory investigation to highly selected clinicians who have completed their training in medical or pediatric oncology. The availability of a wide spectrum of laboratories within the DFCI offers an unusually fertile environment for the exchange of ideas and for collaboration in the design of research programs. Training will continue to be provided through regularly scheduled lectures, clinical and research conferences, and """"""""bench laboratory activities"""""""". Trainees will also be required to participate in the """"""""Harvard Program in the Practice of Scientific Investigation."""""""" as a means of providing instruction in medical ethics and scientific integrity. The research facilities of the DPCI continue to mature with construction well underway for an additional laboratory building, the Richard A. and Susan P. Smith Research laboratories, scheduled for occupancy early in 1998, which will provide six floors for finished research laboratory space as well as animal research laboratories, research administration, and support functions. Twenty-five separate divisions and/or laboratories including Medical and Pediatric Oncology, Cancer Epidemiology and Control, Biostatistics, Hematologic Malignancies, Tumor Immunology, Cancer Pharmacology, Cell Growth and Regulation, Neoplastic Disease Mechanisms, and Human Cancer Genetics offer a wide panoply of investigative opportunities. Trainees supported by this proposal are able to select from among all of these laboratories as to the area in which they wish to conduct their research. All members of the Institute staff hold faculty appointments at Harvard University and participate in classroom presentations in laboratory and clinical research training. In addition to training support provided by this institutional grant, DFCI investigators also participate in pre and postdoctoral training programs at Harvard University through their departmental faculty appointments or at neighboring Harvard-affiliated hospitals. The goal of this program is to encourage the development of academic oncologists. It is expected that at the conclusion of their training, those individuals supported by this program will have the capability for designing, initiating, and completing individual research projects, independently or with minimal supervision, and soon thereafter will be able to establish themselves as independent research investigators. As in the past, it is anticipated that some will remain at the DFCI upon successfully completing their training and will eventually become permanent members of the Institute's research staff.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Cancer Research Manpower and Education Review Committee (CRME)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Kapp, Friedrich G; Perlin, Julie R; Hagedorn, Elliott J et al. (2018) Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche. Nature 558:445-448
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388
Gannon, Hugh S; Zou, Tao; Kiessling, Michael K et al. (2018) Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 9:5450
Boija, Ann; Klein, Isaac A; Sabari, Benjamin R et al. (2018) Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains. Cell 175:1842-1855.e16
Lampson, Benjamin L; Brown, Jennifer R (2018) Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol 11:185-194
Aref, Amir R; Campisi, Marco; Ivanova, Elena et al. (2018) 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip 18:3129-3143
Lampson, Benjamin L; Brown, Jennifer R (2017) PI3K?-selective and PI3K?/?-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26:1267-1279
Lampson, Benjamin L; Davids, Matthew S (2017) The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 12:11-19
Meehan, Terrence F; Conte, Nathalie; Goldstein, Theodore et al. (2017) PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res 77:e62-e66

Showing the most recent 10 out of 241 publications